Company intelligence / Profile preview

Propagenix

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Propagenix demonstrated the ability to massively expand and differentiate autologous epithelial stem cells for transplantation of skin, airway, and cornea, supported by key application data in personalized diagnostics and functional patient-specific tissue engineering. Its platform has shown utility in generating functional cells for transplantation and diagnostic use in cystic fibrosis and oncology

Therapeutic areas: PulmonologyOncologyDermatologyOther
Modalities: Cell therapyEngineered tissue therapy
Industry: Biotech

Partnerships

STEMCELL Technologies (licensee, then acquirer)Georgetown University (technology licensor)Over ten major biopharmaceutical and life science firms (unnamed product licensing/partnering)

Beyond the preview

Go deeper on Propagenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propagenix.

Explore the full profile